NOT KNOWN DETAILS ABOUT MOLNUPIRAVIR

Pharmacological inhibition with the ataxia telangiectasia and Rad3-relevant protein serine/threonine kinase (ATR; generally known as FRAP-similar protein (FRP1)) has emerged to be a promising tactic for cancer therapy that exploits synthetic lethal interactions with proteins associated with DNA damage fix, overcomes resistance to other therapies an